Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in
myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing
allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …

Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic
hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed …

Therapeutic management of patients with primary or secondary myelofibrosis (MF) who
experience relapse or graft failure following allogeneic haematopoietic cell transplantation …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF …

Despite the curative potential of allogeneic hematopoietic cell transplantation (HCT) for
myelofibrosis (MF), a significant number of patients with MF do not undergo HCT. Factors …

Abstract Abstract 3085 The International Working Group (IWG) has determined that
prognosis in myelofibrosis is predicted by a scoring system that includes the following …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …